Kodiak Sciences (KOD) Other financing activities (2018 - 2026)

Kodiak Sciences (KOD) reported Other financing activities of $303000.0 for Q1 2026, down 99.7% quarter-over-quarter from $99.6 million in Q1 2020.

Kodiak Sciences (KOD) Other financing activities (2018 - 2026) Analysis & Trends

Kodiak Sciences has reported Other financing activities for 3 years, with the latest figure at $303000.0 in Q1 2026.

For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $303000.0; the trailing twelve-month figure through Mar 2026 stood at $303000.0 (changed N/A YoY), and the FY2020 full-year result was $99.6 million, changed N/A from the prior year.
Other financing activities for Q1 2026 stood at $303000.0, down from $99.6 million in the prior quarter.
The five-year high for Other financing activities was $303000.0 in Q1 2026, with the low at $303000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Kodiak Sciences	1.95 Bn	1.95 Bn	-

Download Data